Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000707088 | SCV000836169 | likely benign | Tuberous sclerosis 2 | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001575500 | SCV001802508 | likely benign | not provided | 2020-12-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000707088 | SCV002039268 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002440551 | SCV002752491 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-08-15 | criteria provided, single submitter | clinical testing | The p.S983C variant (also known as c.2948C>G), located in coding exon 25 of the TSC2 gene, results from a C to G substitution at nucleotide position 2948. The serine at codon 983 is replaced by cysteine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004544953 | SCV004773843 | likely benign | TSC2-related disorder | 2023-12-18 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |